Get Premium to unlock powerful stock data
NAS:AKBA (USA)  
Akebia Therapeutics Inc logo

Akebia Therapeutics Inc

$ 0.39 +0.0359 (+10.17%) 08:08 PM EST
P/E:
At Loss
P/B:
2.74
Market Cap:
$ 71.39M
Enterprise V:
$ 32.02M
Volume:
74.89M
Avg Vol (2M):
13.25M
Also Trade In:
Volume:
74.89M
Market Cap $:
71.39M
PE Ratio:
At Loss
Avg Vol (2-Month):
13.25M
Enterprise Value $:
32.02M
PB Ratio:
2.74
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Akebia Therapeutics Inc
NAICS : 325412 SIC : 2834
245 First Street, Suite 1100, Cambridge, MA, USA, 02142
Description
Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States.
Name Current Vs Industry Vs History
Cash-To-Debt 1.29
Equity-to-Asset 0.05
Debt-to-Equity 5.18
Debt-to-EBITDA -0.61
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -4.95
Distress
Grey
Safe
Beneish M-Score -3.13
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 59.5
9-Day RSI 54.64
14-Day RSI 49.66
6-1 Month Momentum % -84.47
12-1 Month Momentum % -90.96

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.19
Quick Ratio 1.04
Cash Ratio 0.69
Days Inventory 94.33
Days Sales Outstanding 77.06
Days Payable 75.07

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -14.8

Financials (Next Earnings Date:2022-08-05 Est.)

AKBA's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:AKBA

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 222.973
EPS (TTM) ($) -1.6
Beta 1.43
Volatility % 81.71
14-Day RSI 49.66
14-Day ATR ($) 0.061613
20-Day SMA ($) 0.377885
12-1 Month Momentum % -90.96
52-Week Range ($) 0.3 - 3.9
Shares Outstanding (Mil) 183.53

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Akebia Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More